ResApp receives notice of allowance for core patent in Japan

ResApp receives notice of allowance for core patent in Japan

Monday, November 05, 2018 

ResApp Health Limited, a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for its Japanese patent application 2015-502020 titled “A Method and Apparatus for Processing Patient Sounds” covering the use of a cough sound based audio processing pipeline for diagnosing respiratory disease. The patent protects a key component of ResAppDx, ResApp’s smartphone application for diagnosing acute respiratory disease, and has an expiry date of 28 March 2033.

This patent is the third member of the patent family to be accepted, following acceptances from the United States Patent and Trademark Office and IP Australia. Patent applications covering similar subject matter are pending in Europe, China and South Korea.

“As an aging population, shortage of doctors and rising healthcare costs put pressure on the Japanese healthcare system, the use of telehealth in Japan is growing and was recently accelerated by deregulation allowing for health insurance coverage,” said Tony Keating, CEO and Managing Director of ResApp. “The granting of our core patent by the Japanese Patent Office is an important part of our commercialisation strategy in Japan and further strengthens our global intellectual property position.” 

Source: Company Press Release

Key Facts
    • News Category

      Intellectual Property

    • Company

      ResApp Health Ltd

    • Country

      Asia-Pacific > Australia
      Asia-Pacific > Japan

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 44 = 48